Home Newsfeeds Morgan Stanley Maintains Overweight on Plains All American, Raises Price Target to $16

Morgan Stanley Maintains Overweight on Plains All American, Raises Price Target to $16

Morgan Stanley analyst Robert Kad maintains Plains All American (NASDAQ:PAA) with a Overweight and raises the price target from $15 to $16.

byBenzinga Newsdesk

October 19, 2022

1 minute read

Morgan Stanley analyst Robert Kad maintains Plains All American (NASDAQ:PAA) with a Overweight and raises the price target from $15 to $16.

Janney Montgomery Scott Downgrades SmartFinancial to Neutral, Announces $30 Price Target

By Benzinga Newsdesk

January 25, 8:13 AM

Janney Montgomery Scott analyst Feddie Strickland downgrades SmartFinancial (NASDAQ:SMBK) from Buy to Neutral and announces $30 price target.

SMBK

Proxy Truces On The Rise At Catalent: Elliott Builds Significant Stake, Calls For Board Shake-Up

By Vandana Singh

July 20, 8:08 AM

Elliott Investment Management, an activist shareholder, has reportedly acquired a substantial stake in Catalent Inc (NYSE: CTLT). They are now advocating for a significant overhaul of the contract manufacturer's board.

CTLT

Barclays Upgrades Gap to Equal-Weight, Raises Price Target to $9

By Benzinga Newsdesk

August 31, 7:29 AM

Barclays analyst Adrienne Yih upgrades Gap (NYSE:GPS) from Underweight to Equal-Weight and raises the price target from $6 to $9.

GPS

XBiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke

By Benzinga Newsdesk

September 26, 9:05 AM

XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled

XBIT

Morgan Stanley Maintains Overweight on Plains All American, Raises Price Target to $16

Related Posts

Janney Montgomery Scott Downgrades SmartFinancial to Neutral, Announces $30 Price Target

Proxy Truces On The Rise At Catalent: Elliott Builds Significant Stake, Calls For Board Shake-Up

Barclays Upgrades Gap to Equal-Weight, Raises Price Target to $9

XBiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke